LatestJury Awards $6 Million to Ousted Cambridge Scientist David Sabatini in Damages Case
Health

Brain PET Scans Help Select and Monitor Patients for New Alzheimer's Drugs

Brain PET Scans Help Select and Monitor Patients for New Alzheimer's Drugs
Alzheimer's Disease
Summary

Nuclear medicine imaging is increasingly vital in diagnosing and treating Alzheimer's disease, enabling clinicians to visualize the biological changes underlying the condition. Amyloid PET imaging confirms the presence of amyloid pathology and guides treatment decisions for patients receiving anti-amyloid medications, while tau PET scans provide critical information about disease progression and prognosis. These advanced imaging techniques allow healthcare providers to personalize treatment approaches and better monitor therapeutic responses in Alzheimer's patients.

Medical Xpress

Originally published on

Medical Xpress

Read full article(opens in new tab)

Fetched: October 17, 2026 at 10:00 AM

Related News

More news you might be interested in

View all
Jury Awards $6 Million to Ousted Cambridge Scientist David Sabatini in Damages Case
Health

Jury Awards $6 Million to Ousted Cambridge Scientist David Sabatini in Damages Case

A jury has awarded $6 million in damages to David Sabatini, a prominent scientist whose career was derailed following accusations of inappropriate sexual conduct in his laboratory. The case highlights ongoing workplace conduct issues within academic research institutions and the legal complexities surrounding allegations in scientific environments. This verdict underscores the importance of fair investigation procedures and due process in high-stakes professional settings. The outcome raises questions about institutional accountability and proper protocols for handling workplace misconduct allegations in academia.

8 hours ago
STAT News
Stroke Risk Linked to Controllable Health Factors, Not Ethnicity
Health
DiabetesHeart Disease

Stroke Risk Linked to Controllable Health Factors, Not Ethnicity

A groundbreaking study from King's College London reveals that ethnic disparities in stroke risk are primarily explained by differences in traditional risk factors such as diabetes and high blood pressure, rather than ethnicity itself. The research challenges the notion that certain populations face inherently higher stroke risk due to genetic or ethnic factors. Instead, the findings emphasize that managing controllable conditions like hypertension, diabetes, and other cardiovascular risk factors is crucial for stroke prevention across all communities. This discovery has important implications for public health strategies, suggesting that targeted interventions focusing on risk factor management could help reduce stroke disparities among different ethnic groups.

9 hours ago
Medical Xpress
Global Burden of Acne Increased from 1990 to 2023, Study Shows
Health
Acne

Global Burden of Acne Increased from 1990 to 2023, Study Shows

A new study published in JAMA Dermatology reveals that the global burden of acne has significantly increased between 1990 and 2023, with projections indicating this trend will continue through 2050. The research highlights acne as an increasingly prevalent health concern affecting millions worldwide. This surge in acne burden underscores the growing need for effective treatment options and dermatological care. Understanding these trends helps healthcare providers better prepare resources and develop strategies to address this common skin condition affecting people across all age groups.

11 hours ago
Medical Xpress
Early MS Treatments Show Different Effects on Relapses and Brain Damage, Not Disability
Health
Multiple Sclerosis

Early MS Treatments Show Different Effects on Relapses and Brain Damage, Not Disability

A new study reveals that IV medications targeting B cells in the immune system reduce relapses by 62% compared to oral pills commonly prescribed for early-stage multiple sclerosis. While B-cell targeting therapies show promise in controlling disease activity and reducing brain scarring, researchers found no significant difference in disability progression between the two treatment approaches. This finding suggests that early intervention with IV immunotherapies may offer better protection against relapses in MS patients, though long-term disability outcomes remain comparable. The research highlights the importance of individualized treatment planning for MS patients in their early disease stages.

12 hours ago
Medical Xpress